Prescient partners with global cancer heavyweight to develop new treatments
Prescient Therapeutics (ASX:PTX) has formed a cancer research partnership with the world-renowned Peter MacCallum Cancer Centre,...
Prescient Therapeutics (ASX:PTX) has formed a cancer research partnership with the world-renowned Peter MacCallum Cancer Centre,...
Prescient Therapeutics (ASX: PTX) has moved closer to developing its unique CAR-T cancer technology after revealing...
Special Report: Biotech company Prescient Therapeutics is advancing to next-stage trials for its personalised treatments...
Every year 45,000 of the most respected professionals in oncology gather at the American Society...
Last month, the best and brightest minds in oncology gathered (virtually) for the American Society...
Two of Prescient Therapeutics' (PTX) assets have been handpicked for a COVID-19 antiviral testing program....
Prescient Therapeutics Limited (ASX:PTX) has signed a research agreement with the Peter Doherty Institute for Infection and...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has revealed two of its assets have been selected...
PTX has acquired the exclusive global licence to a universal immune receptor (UIR) platform from...
Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke joined Steve Darling from Proactive...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.